Abstract. K-ras (KRAS) is mutated in 40-50% of human colorectal adenomas and carcinomas and plays key roles in cell proliferation, apoptosis, motility and differentiation, but its functional contribution to intestinal tumourigenesis in vivo remains incompletely understood. We have previously crossed K-ras
Introduction
Human colorectal carcinomas accumulate multiple mutations in cancer-related genes, including oncogenes such as KRAS and tumour suppressor genes, such as APC (adenomatous polyposis coli), SMAD 2/4, p53 and others (1, 2) . KRAS mutations can be detected at all stages of colorectal cancer development, from dysplastic aberrant crypt foci (AcF) and hyperplasic polyps to late adenomas and carcinomas (3, 4) . Mutational activation of the KRAS gene reduces or abolishes the protein's intrinsic gtpase activity, locking it in its gtp-bound conformation that results in constitutive activation of MApK and pI3K/AKt signal transduction pathways (5) , modulating cell proliferation, apoptosis, senescence, motility and differentiation (6) (7) (8) (9) (10) , but its roles in colorectal tumour initiation and progression are still incompletely understood.
the APC gene, is known as the 'gatekeeper' of colorectal cancer, and is mutated in >80% of colorectal adenomas and carcinomas. Inherited APC defects give rise to the syndrome of familial adenomatous polyposis coli (FAp) manifested by the formation of hundreds of colorectal adenomas (11) . the Apc Min/+ mouse model harbours a dominant germline mutation of Apc at codon 850 of the mouse homologue and displays Apc-driven tumourigenesis almost entirely in the small intestines with very few adenomas forming in the large intestines (12) . Investigation of adenomas from both FAp patients and Apc Min/+ mice (each with one inherited Apc gene mutation) has shown that the second allele is almost always mutated or deleted in the adenomas formed. this indicates that mutation or loss of APC alleles is the most important alteration for the initiation of intestinal tumourigenesis (13) (14) (15) .
Although colorectal tumours appear to arise via a multistep process, it is not clear which genetic alterations are required
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FeIjun luo 1, 2 , george poulogIAnnIs 1 , HongtAo ye 1 , rIFAt HAMoudI 1 and MArK j. Arends for the formation of adenomas or whether this process involves the cooperation of specific mutated genes. KRAS and APC mutations both occur during the early stages of colorectal adenoma formation, including dysplastic aberrant crypt foci, early monocryptal adenomas, oligocryptal adenomas and established adenomas. However, the precise contributions of mutated KRAS and APC to intestinal tumourigenesis are still elusive. In vitro studies have shown that when these genes are both mutated, they promote transformation of colonic epithelial cell lines suggesting synergistic cooperation, however in vivo studies are contradictory (16, 17) . We have previously generated mice with an inducible K-ras
Val12 transgene and crossed these with Ah-Cre mice to produce K-ras Val12 /Cre offspring (18) . Following treatment with β-naphthoflavone to induce cre-mediated transgene recombination, activation of intestinal expression of K-ras
Val12
4A and 4B had no significant effect on the formation of intestinal adenomas (18) . In the current study, we crossed these intestinal inducible K-ras Val12 /Cre mice with Apc Min/+ mice to investigate whether combined mutation of these two genes can cooperate to modify intestinal tumourigenesis. the double mutant offspring have significantly reduced survival due to increased numbers of intestinal adenomas, particularly in the large intestines, compared with Apc Min/+ control mice. the data presented here clearly show that mutant K-ras
Val12 accelerates Apc-driven large intestinal tumourigenesis in vivo.
Materials and methods
Mice. Apc
Min/+ mice have a nonsense mutation at codon 850 in the Apc gene (12) . K-ras Val12 mice carry a codon 12 glycine to Valine mutation and express both K-ras Val12 4A and 4B isoform transcripts in the intestines upon β-naphthoflavone-induction of cre-mediated LoxP recombination (18) . All animals had free access to standard laboratory diet and water ad libitum and were maintained on a 12-h light/12-h dark schedule. the animal experimental protocols were carried out under uK Home Office licence.
Genotyping of mice by polymerase chain reaction (PCR).
Tail material was digested overnight at 55˚C in 500 µl DNA lysis buffer. dnA was extracted by standard procedures and amplified in a 30µl PCR reaction. The quality of genomic dnA samples was estimated by amplifying a wild-type Apc gene fragment (18) . the pcr conditions that were used for genotyping K-ras
Val12 and Cre mice were as follows: 95˚C for 30 sec, 60˚C for 30 sec and 72˚C for 45 sec for 35 cycles (18, 19) . the genotyping assays for Apc Min/+ mice have been described previously (20) .
Analysis of intestinal tumours. the total number of intestinal polyps was assessed for each mouse. the whole intestinal tract was removed, rinsed gently in pBs, opened lengthwise, and spread out flat on filter paper. All polyps were counted under a dissecting microscope at x15 magnification and the smallest adenomatous polyps identified were about 0.5 mm in diameter. tumours were cut in two and half was used for extraction of dnA, rnA and protein and the other half for formalin fixation and histopathological analysis. the tumour samples from the small and large intestines were processed for paraffin embedding following fixation in 10% neutral-buffered formalin solution and sections were prepared for H&e staining and immunohistochemistry as described previously (21, 22) .
Analysis of LoxP site recombination by PCR and DNA sequencing.
In order to induce Cre expression via the Ah promoter, the Ah-Cre containing mice were injected with 80.0 mg/kg β-naphthoflavone (β-nF) (sigma, dorset, uK) dissolved in corn oil for 6 days as described previously (19) . genomic dnA was prepared from intestinal tumours and non-tumour-bearing intestinal tissue samples by overnight proteinase K digestion and purification using a QIAamp tissue kit (Qiagen, uK). transgene recombination was detected by pcr using the primers: re-cMV, 5'-tcAgAtcActAgAAgctttAttgcgg-3' (sense primer), which is located in the cMV promoter; and re-K-ras Val12 , 5'-ttctgAAttAgctgtAtcgtcAAggc-3' (antisense primer), which is located in exon 3 of the K-ras transgene to generate a ~500 bp pcr product (18) . the pcr assay detected cre-mediated recombination of the two LoxP sites that flank the 'stop' cassette. Following removal of the 'stop' cassette by recombination, the cMV promoter lies immediately adjacent to the transgene and drives expression of the K-ras Val12 4A and 4B transcripts. In some experiments the amplified PCR product was DNA sequenced by standard methods to demonstrate loss of the 'stop' cassette and retention of only a single LoxP site between the cMV promoter and the human K-ras Val12 transgene.
Analysis of expression of K-ras
Val12
. Human K-ras Val12 4A expression was determined using the primer pair K-ras 4A upstream primer (5'-AgtgcAAtgAgggAccAgtAcAtgAgg-3'), located in K-ras exon 3, and K-ras 4A downstream primer (5 ' -t t t g c t g At g t t t c A AtA A A Ag g A At t-3 ' ) located in K-ras exon 4A. Human K-ras Val12 4B expression was determined using the K-ras 4B upstream primer (5'-gtAcctAtggtcctAgtAggAAAtAAA-3'), also located in human K-ras exon 3; and K-ras 4B downstream primer (5'-ctgAtgtttcAAtAAAggAAttccA-3') located in human K-ras exon 4B. the pcr product sizes for K-ras 4A and 4B were 248 and 159 bp, respectively. For quantitative rt-pcr, 100 ng of total rnA of different tissue samples was reverse transcribed in 25 ml volume using the iTaq SYBR Green kit RT-PCR kit (Bio-Rad, UK). RT-qPCR was performed using the following PCR cycling conditions: 95˚C for 3 min, followed by 45 cycles of 95˚C for 15 sec and 60˚C for 1 min.
Western blotting and immunohistochemical analysis. For Western blot analysis, fresh tissue samples were lysed in protein lysis buffer containing 50 mM tris-Hcl (pH 7.4), 150 mM nacl, 0.5% np-40 and protease inhibitors. soluble protein lysates were quantified using the BCA Protein Assay kit (pierce, uK). total proteins were separated by 15% sds-pAge, transferred to nitrocellulose membranes (schleicher and scheull, uK), and incubated with the corresponding antibodies including anti-K-ras Val12 (oncogene co., usA), and anti-cre rabbit polyclonal antibody (novagen, usA). Blots were hybridized with antibodies in 1:1000 dilutions and visualization was performed with chemiluminescence. the pMApK Family rabbit mAb sampler Kit and the pAKt pathway sampler Kit (cell signaling, usA) were used for MApK and AKt pathway protein analysis by Western blotting. Immunohistochemical analysis was performed with the goat anti-gastrin polyclonal antibody (santa cruz Biotechnology, usA), the rabbit anti-cox-2 monoclonal antibody and the rabbit anti-vascular endothelial growth factor (VegF) polyclonal antibody (both from novus Biologicals, usA) as described previously (21, 22) .
RT-qPCR analysis.
Real-time quantitative reverse transcription PCR (real-time RT-qPCR) was carried out to measure the relative expression levels of selected target genes (table I shows PCR primer sequences) using the comparative Ct method that has been described previously (18, (20) (21) (22) . gene expression levels were normalized against β-actin (using the following formulas: ∆∆ct = ∆ct test-∆ct control, fold change = 2 -∆∆ct ).
Statistical analysis. the spss statistical package was used for all statistical analyses. student's t-tests were used to compare adenoma numbers and Kaplan-Meier curves were used to estimate the time-related probabilities of survival among the different mouse cohorts. the log-rank test was used to estimate the significance of differences between survival distributions. (Fig. 1) , showing an overall 6-fold increase in the total number of large intestinal adenomas in the K-ras Val12 /Cre/ Apc Min/+ mice compared with Apc Min/+ mice. All small and large intestinal tumours were shown to be moderately dysplastic adenomas histopathologically with no evidence of invasive malignancy (Fig. 2) .
Results
Intestinal tumour formation is increased in K-ras
The K-ras
Val12 transgene is recombined and expressed in the intestinal adenomas of K-ras Val12 /Cre/Apc Min/+ mice. A pcr assay was used to detect recombination occurring at the two LoxP sites (flanking the 'Stop' cassette) in the K-ras
Val12 transgene, in 8 out of 10 large intestinal tumours (Fig. 3A) . This was confirmed by DNA sequencing of the PCR products (data not shown) which showed that the 'stop' cassette had been deleted between the two LoxP sites, leaving only one LoxP site between the cMV promoter and the adjacent K-ras sequence and confirmed the presence of the g12V mutation in the transgene. Val12 /Cre/Apc Min/+ mice was associated with immunohistochemical evidence of increased perK1/2 and pAkt, indicating activation of the MapK and Akt pathways, respectively. Immunohistochemical assessment also showed increased nuclear localisation of β-catenin, consistent with enhanced signaling of the Wnt pathway in these adenomas and this is in keeping with increased immunohistochemical expression of the Wnt-target gene VEGF (Fig. 4) . Quantitative reverse-transcription pcr showed increased relative transcript levels of the stem cell associated genes Trap1a and Tcl-1 (10) large intestine tissues from the cohorts in the middle of the heatmap (Fig. 5) . this pattern indicates that the combination of mutant K-ras and mutant Apc modulates gene expression in characteristic ways in these intestinal tumours and suggests that expression of mutated K-ras activates the MapK, Akt and Wnt downstream signaling pathways consistent with synergistic effects of mutant K-ras and mutant Apc on a subset of Wnt pathway target genes in adenomas in vivo. 
transgene recombination and expression of K-ras
Val12 in large intestinal adenomas. (A) transgene recombination assay was performed by pcr amplification of genomic DNA extracted from adenomas, using primers located in the CMV promoter and K-ras Val12 exon 3, resulting in a ~500 bp fragment, only if cre-mediated recombination at the LoxP sites had occurred in the K-ras
Val12 transgene, as seen in the large intestinal tumours lIt1 to lIt4 and LIT7 to LIT10. Amplification of a DNA fragment of the Apc gene was used as a control for adequate quality of genomic DNA.
(B) RT-PCR analysis of the expression of K-ras
Val12 4A and 4B transcript isoforms in selected large intestinal tumours (lIt1-4) from K-ras Val12 /Cre/Apc Min/+ transgenic mice. rt-pcr amplification of β-actin transcript was used to control the quality of RNA samples. (C) Western blot analysis demonstrating the expression of mutant K-Ras protein using anti-K-ras Val12 protein antibody in selected large intestinal tumours (lIt1-4) from K-ras Val12 /Cre/Apc Min/+ mice, whereas lIt 5 and 6 showed no transgene recombination or expression.
Discussion
the progression of human colorectal cancer from normal to adenoma to carcinoma involves many genetic and epigenetic alterations including APC, KRAS, BRAF, PIK3CA, β-catenin, SMAD2 and 4 and TP53 genes amongst others (23, 24) . KRAS mutations have been detected in clusters of abnormal crypts in the colonic mucosa known as aberrant crypt foci (AcF), as well as in early and established adenomas and in canceradjacent morphologically normal colon (5, 25) . one of the commonest mutations that activate the KRAS oncogene is the codon 12 glycine to valine mutation and this has been associated with colorectal cancers with a poor prognosis (26) . Although activating mutations of KRAS are associated with early to intermediate stages of adenoma formation, it is still unclear whether their tumourigenic effects occur only in the context of pre-existing APC or other gene mutations (27) . the view that the oncogenic effects of mutated KRAS depend upon previous APC mutations in intestinal cancer has recently been challenged. A study on the mutational status of AcF, which are thought to be putative precursor lesions of colorectal adenomas and cancers, has demonstrated the presence of frequent KRAS mutations, in the absence of mutations of APC or its downstream target β-catenin (28) . To address the question whether activated KRAS is able to initiate intestinal tumour formation or rather depends on previous APC mutations, we developed a Cre/LoxP-based transgenic system that expresses the cre recombinase under induction of the Ah promoter by β-nF, which drives recombination and expression of the mutant K-ras transgene in the murine adult intestinal crypt stem cells with a high degree of spatial-temporal control.
this transgenic line of mice has a single integrated copy of the K-ras
Val12 transgene and following β-nF-mediated induction we detected only minimal phenotypic changes in the intestines of these mice with just two intestinal tumours in 2/20 mice over a period of two years (one adenoma in the large intestines and one adenoma in the small intestines), while another 8 mice were killed after one year and showed no intestinal tumours (18) . this is consistent with the appearance of only a few intestinal tumours in other previous studies (29) , and indicates that expression of mutated K-ras alone in intestinal epithelium is unable to drive the initiation of intestinal tumour formation. johnson and colleagues used a transgenic model, in which the activation of mutant K-ras was generated at random by spontaneous recombination occurring within the allele and showed that these mice were predisposed to a range of tumour types, predominantly early onset lung adenocarcinomas, but no intestinal tumours (16) . janssen and colleagues have also generated mice with a mutated K-ras gene driven by the regulatory region of the murine villin promoter, however these villin-K-ras Val12 mice developed just two tumours over a 6 month period (29) . the in vivo oncogenic activity of K-ras appears to be dependent on cellular context (30) and requires other additional mutations in order to contribute to intestinal tumourigenesis, such as mutant Apc or defective mismatch repair gene Msh2 (18) . johnson and colleagues produced a double mutant mouse model that carried both a mutated K-ras allele and the Apc Min/+ allele, but the tumour type and frequency found in these mice did not change. However, it is not clear whether K-ras was activated in the intestinal tumours that had formed in these mice. sansom and colleagues did show synergistic co-operation between mutant K-ras and mutant Apc, mostly in kidney tumour formation but also in intestinal tumourigenesis, although this study did not detect any differences in the activation of the raf/MeK/ erK pathway in the intestinal tumours (17) . Here, we have shown that mutated K-ras significantly accelerates intestinal adenomagenesis on a background of inherited Apc mutation, with a 6-fold increase in adenomas in the large intestines, with significantly reduced survival. We have confirmed this result for mice bearing a K-ras
Val12 transgene in the current study as well as mice with a K-ras Asp12 transgene in our previous study (20) , and there was no significant difference in the intestinal oncogenic effect between these two types of K-ras mutation.
previous studies have shown that expression of mutant K-ras Val12 in either mouse embryonic stem (es) cells or mutant K-ras transgenic mice was associated with changes in expression of a range of gene transcripts and proteins, including stem cell associated genes and components of the Mapk and Akt pathway genes (10, 18, (20) (21) (22) . Quantitative rt-pcr and immunohistochemical expression analysis of the intestinal tumours Val12 has been shown to stimulate Wnt signaling in colonic cancer through inhibition of GSK-3β (32), which is regulated by the activation of the pI3K/Akt pathway. Wnt3a stimulation of g1/s phase cell cycle progression was reduced after treatment with an erk inhibitor, suggesting that Wnt3a could promote proliferation via an erk-dependent pathway (33) . the expression of Gastrin, as a tumour growth factor, is significantly increased in some colonic cancers compared with their corresponding normal colonic mucosa and is known to be induced upon activation of the raf-MeK-erK signal transduction pathway. Interestingly, the Wnt signaling pathway moderately stimulates the Gastrin gene promoter, and chakladar and colleagues (34) found a strong (25-to 40-fold) synergistic stimulation of the Gastrin promoter by the combination of oncogenic β-catenin and K-ras overexpression. Gastrin promoter activation could be further enhanced or suppressed by the co-expression of wild-type SMAD4 or a dominant negative mutant of SMAD4, supporting co-operation between oncogenic Wnt and ras signaling pathways inducing enhanced Gastrin expression (34) .
In vivo, Apc
Min/+ mice that overexpress one of the alternatively processed forms of gastrin, known as glycine-extended Gastrin, show a significant increase in intestinal adenomatous polyp number. on the contrary, Gastrin-deficient Apc Min/+ mice showed a marked decrease in intestinal polyp number and a significantly decreased adenoma proliferation rate (33) . the immunohistochemical and rt-pcr expression data also demonstrated that adenomas from K-ras Val12 /Apc Min/+ mice showed increased expression of Gastrin.
the t lymphoma invasion and metastasis 1 gene (Tiam1) product has been suggested to be an important effector pathway for some of the effects of mutated K-ras. Tiam1 -/-mice were shown to be resistant to the development of mutant ras-induced skin tumours following treatment with the carcinogen 7, 12-dimethylbenzanthracene and promoter 12-o-tetra-decanoylphorbol-13-acetate. Moreover, the few tumours that were detected in Tiam1 -/-mice grew more slowly than the tumours that were found in wild-type mice. Tiam1-deficient mouse embryonic fibroblasts were also resistant to ras Val12 -induced foci formation. Hence, Tiam1 was shown to be a critical regulator of ras-induced tumour formation (35) . Interestingly, Tiam1 is also a Wnt-responsive gene that is expressed in the base of intestinal crypts and is found to be up-regulated in the intestinal adenomas of Apc Min/+ mice and human colonic adenomas. comparison of polyp formation in Apc Min/+ mice expressing or lacking Tiam1, showed that Tiam1 deficiency significantly reduced the formation of intestinal polyps in vivo (35) . Here, we showed that adenomas from mutated K-ras and Apc Min/+ mice showed increased Tiam1 expression, in support of interaction between the K-ras-tiam1-rac and canonical Wnt-signaling pathways. the rt-pcr expression data also demonstrated that mutated K-ras co-operates with Apc Min/+ to induce increased expression of Cox-2 in adenomas in vivo, which is consistent with previous findings that co-expression of both mutant β-catenin and K-ras increased cox-2 protein expression levels in vitro (36) .
overall, this study shows that whereas intestinal expression of K-ras Val12 alone does not significantly initiate adenoma formation, when combined with mutant Apc, the double mutant K-ras Val12 /Cre/Apc Min/+ mice show a dramatic acceleration of intestinal adenomagenesis, which is associated with significantly reduced survival, due to the 6-fold significant increase of adenomas in the large intestines and the 1.86-fold increase in the small intestines. tumour expression analysis showed that expression of mutant K-ras in adenomas from K-ras Val12 / Cre/Apc Min/+ mice was associated with increased expression of many genes that are known to be regulated by the MapK, Akt and Wnt signaling pathways, including Tiam1, Gastrin, CD44, uPA, Igfbp4, VEGF and Cox-2 as well as increased nuclear accumulation of β-catenin, consistent with synergism between Wnt and K-ras signaling pathways.
